NEWBURY PARK, Calif.–Electronic Sensor Technology (EST) (OTCBB: ESNR), a leading provider of innovative homeland security, environmental solutions and healthcare solutions, announces the receipt of an order of 4 units of the zNose Model 4200 from Menssana Research Inc., of Fort Lee, New Jersey.

Dr. Michael Phillips, Founder and CEO of Menssana Research, has pioneered breath analysis by developing new non-invasive screening tests for medical conditions such as cancer and tuberculosis. “We are pleased to be associated with Dr. Phillips and his company,” said Dr. Lim CEO of Electronic Sensor Technology Inc.

About Menssana Research:

Menssana Research is the leading developer of advanced new breath tests to detect diseases in their earliest and most treatable stages. The National Institutes of Health has funded Menssana to evaluate breath testing for lung cancer, breast cancer, heart transplant rejection, ischemic heart disease, kidney disease and diabetes mellitus.

For more information on the use of the zNose® for environmental, security and healthcare, click the following link: http://www.estcal.com/

About Electronic Sensor Technology:

Founded in 1995, Electronic Sensor Technology has developed and patented a chemical vapor analysis process with applications for the homeland security and environment markets.

SEC Filings and Forward-Looking Statements

This press release includes forward-looking statements, including the Company’s expectations regarding its ability to develop and access capital markets and its ability to achieve expected results in the chemical detection and analysis industry. The forward-looking statements are identified through use of the words “potential,” “anticipate,” “expect,” “planned” and other words of similar meaning. These forward-looking statements may be affected by the risks and uncertainties inherent in the chemical detection and analysis industry and in the Company’s business. The Company cautions readers that certain important factors may have affected and could in the future affect the Company’s beliefs and expectations, and could cause the actual results to differ materially from those expressed in any forward-looking statement made by or on behalf of the Company. For a discussion of these factors, please refer to our recent filings with the Securities and Exchange Commission, including our most recent report on Form 10-KSB. The Company undertakes no obligation to update forward-looking statements to reflect events or circumstances after the date hereof.